| Pharmaceuticals Industry | Healthcare Sector | Mr. Cuilong Zhang CEO | XBER Exchange | HK1093012172 ISIN |
| China Country | 20,300 Employees | 4 Jun 2025 Last Dividend | 16 Oct 2020 Last Split | - IPO Date |
CSPC Pharmaceutical Group Limited, positioned as an investment holding entity, delves into the realms of research, development, manufacturing, and sales of pharmaceutical products not only within the People's Republic of China but also across various regions globally including other parts of Asia, the Americas, and Europe. With its operations segmented into Finished Drugs, Bulk Products, and Functional Food and Others, CSPC stands out for its adeptness in addressing a wide array of medical conditions through its innovative pharmaceutical solutions. The strategic partnership with Pfizer Inc., particularly for the local launch of the COVID-19 oral treatment Nirmatrelvir/Ritonavir in China, underscores its commitment to contributing to global health crises responses. Formerly known as China Pharmaceutical Group Limited, its rebranding to CSPC Pharmaceutical Group Limited in March 2013 signifies a pivotal evolution in its journey since its establishment in 1992. The corporate headquarters nestle in Shijiazhuang, the People's Republic of China, marking its central hub for pioneering healthcare advancements.
With a diversified portfolio addressing a broad spectrum of healthcare needs, from acute medical conditions to chronic illnesses, and a foray into functional foods, CSPC Pharmaceutical Group Limited exemplifies its role as a comprehensive healthcare provider. Through strategic partnerships and a relentless focus on innovation, CSPC continues to pave the way forward in the pharmaceutical industry, offering solutions that significantly improve patient care and treatment outcomes.